Microfluidic system for point of care diagnosis of GBS

用于 GBS 护理点诊断的微流控系统

• 批准号: 6943106
• 负责人: Michel G. Bergeron
• 金额: $ 52.88万
• 依托单位: LAVAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943106
• 关键词: Canada; Streptococcus agalactiae; bacterial genetics; biomedical equipment development; biosensor device; birth; body fluids; clinical research; cooperative study; diagnosis design /evaluation; fluid flow; human subject; infection; interdisciplinary collaboration; microorganism culture; nucleic acid purification; nucleic acid sequence; polymers; portable biomedical equipment; rectum /anus; sample collection; vagina

DESCRIPTION (provided by applicant): This multidisciplinary collaborative research project between investigators of the University of Laval and Infectio Diagnostic (I.D.I.) Inc. in Quebec City and the University of California at Irvine, aims at developing novel, flexible, and rapid diagnostic devices based on nucleic acid testing. The pinnacle in molecular diagnostics is to have a disposable point-of-care handheld device combining nucleic acid extraction, concentration, purification, amplification, and detection to specifically and sensitively detect the target sequences. Such devices would allow the integration of diagnosis and therapy as well as development of personalized medicine. Technologies based on nucleic acid detection that are currently available or under development are slow, complicated, insufficiently sensitive, and expensive. The objective of this application is to merge our expertise in microfluidics and polymeric transducers to design and construct diagnostic devices of the future which do not require prior nucleic acid amplification. A rapid molecular assay for the specific and sensitive detection of Group B Streptococci (GBS) colonization in pregnant women at delivery will be developed. GBS are an important cause of neonatal morbidity and mortality. A portable micro total analysis system (mu/TAS) using a microfluidic platform on a compact disc support will be developed. It will be compact, battery operated and its simple utilization and low cost will make it suitable for testing at a field site, in a clinic, or in hospitals. This novel diagnostic platform will be optimized for GBS detection from vaginal/anal specimens. It will be validated by a pre-clinical study with samples obtained from consenting pregnant women at delivery that will be performed in collaboration with several hospitals. This new technological platform should provide unprecedented point-of-care diagnostic tools for GBS, permitting a better control of antibiotic use, and reducing dissemination of resistant microbes. Moreover, this technology could also be applicable to the detection of other infectious disease agents including biological warfare agents.

描述（由申请人提供）： 魁北克市的Laval大学研究人员和Infectio诊断研究人员（I.D.I.）研究人员与欧文分校的跨学科合作研究项目，旨在开发基于核酸测试的新颖，灵活和快速诊断设备。分子诊断中的顶峰是具有一个可支配的手持式手持设备，该设备结合了核酸提取，浓度，纯化，扩增，并检测到具体，灵敏地检测目标序列。这样的设备将允许整合诊断和治疗以及个性化医学的开发。基于目前可用或正在开发的核酸检测的技术缓慢，复杂，不足敏感且昂贵。该应用的目的是合并我们在微流体和聚合传感器方面的专业知识，以设计和构建未来的诊断设备，而这些设备不需要先前的核酸扩增。将开发出孕妇中B组链球菌（GBS）定殖的特异性和敏感检测的快速分子测定。 GB是新生儿发病率和死亡率的重要原因。将开发使用紧凑型光盘支持上的小流体平台的便携式微流体分析系统（MU/TAS）。它将紧凑，电池操作，其简单利用和低成本将使其适合在现场，诊所或医院的现场测试。这个新颖的诊断平台将通过阴道/肛门标本进行优化，以检测GBS。这将通过一项临床前研究来验证，并通过同意孕妇在分娩时获得的样本将与几家医院合作进行。这个新的技术平台应为GB提供前所未有的护理诊断工具，可以更好地控制抗生素使用，并减少耐药性微生物的传播。此外，该技术也可以适用于检测其他传染病药物在内的，包括生物战剂。